Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-04
2008-11-18
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S046000, C514S047000, C514S048000
Reexamination Certificate
active
07452870
ABSTRACT:
The present invention provides a P2Y12receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4621076 (1986-11-01), Kuzuya et al.
patent: 5049550 (1991-09-01), Zamecnik
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5814609 (1998-09-01), Markland et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6037343 (2000-03-01), Ali
patent: 6040317 (2000-03-01), Duggan et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6528640 (2003-03-01), Beigelman et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6908624 (2005-06-01), Hossainy et al.
patent: 2002/0052337 (2002-05-01), Boyer et al.
patent: 2004/0220133 (2004-11-01), Boyer et al.
patent: 2005/0233062 (2005-10-01), Hossainy et al.
patent: 1407903 (1975-10-01), None
patent: WO 89/04321 (1989-05-01), None
patent: WO 92/01673 (1991-07-01), None
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 97/29456 (1997-08-01), None
patent: WO 98/03182 (1998-01-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 99/01138 (1999-01-01), None
patent: WO 99/32085 (1999-01-01), None
patent: WO 98/28300 (1999-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 00/39145 (2000-06-01), None
patent: WO 00/50024 (2000-08-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-07-01), None
patent: WO 02/16381 (2002-02-01), None
patent: PCT/US01/41818 (2002-03-01), None
patent: WO 94/08593 (2004-04-01), None
patent: WO 2005/040174 (2005-05-01), None
patent: WO 2005/097814 (2005-10-01), None
Aleil et al., “Flow Cytometric Analysis of Intraplatelet VASP Phosphorylation for the Detection of Clopidogrel Resistance in Patients with Ischemic Cardiovascular Diseases”,J. Thromb. Haemost. 3:85-92; 2005.
Alessi, D. et al., “Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle”Biochemistry(1992), 31(34), 8043-54.
Antiplatelet Trialists' Collaboration., “Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death.myocardial infarction. and stroke by prolonged antiplatelet therapy in various categories of patients,”Br. Med. J. 308: 81-106 (1994).
Antiplatelet Trialists' Collaboration., “Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy,”Br. Med. J. 308: 159-168 (1994).
Antman, E. for the TIMI 9a Investigators, “Hirudin in Acute Myocardial Infarction,”Circulation, 90(4):1624-1630 (1994).
Bennett, et al., “Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel”,N. Engl. J. Med., 342;1771-1777; 2000.
Bernat, A., et al., “Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas. (1993) 70(5):812-816.
Bujalowski, W. et al., “Structural Characteristics of the Nucleotide-Binding Site ofEscherichia coliPrimary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs”Biochemistry(1994), 33(15), 4682-94.
Bush, L., et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canie coronary arteries,” Circulation 69(6): 1161-1170, (1984).
Cardullo, R. A. et al., “Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase”Analytical Biochemistry(1990), 188(2), 305-9.
Carvalho-Alves, P. et al., “Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase”Journal of Biological Chemistry(1985), 260(7), 4282-7.
Chapal, J. et al., “Comparative effects of adenosine-5′-triphosphate and related analogs on insulin secretion from the rat pancreas”Fundamental&Clinical Pharmacology(1997), 11(6), 537-545.
Doorty et al., “Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells”,Cardiovascular Pathology12:105-110; 2003.
Douglass et al., INS50589, “A Potent, selective and reversible inhibitor of P2Y12 mediated platelet aggregation”, abstract P848086, 229thACS National Meeting, Mar. 13, 2005.
Folts, J. et al., “Platelet Aggregation In Partially Obstructed Vessels and its Elimination with Asprian,” Circulation 54(3):365-370 (1976).
Frederick, L.G., et al., “The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canie Model of Coronary Artery Thrombosis,” Circulation 93(1):129-134 (1996).
Geiger, J., et al., “Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel,”Arterioscler. Thromb. Vasc. Biol. 19:2007-2011 (1999).
Gurbel et al., “Effect of Loading with Clopidogrel at the Time of Coronary Stenting on Platelet Aggregation and Glycoprotein IIb/IIIa Expression and Platelet-Leukocyte Aggregate Formation”,Am. J. Cardiol. 90:312-315; 2002.
Gurbel et al., “Clopidogrel for Coronary Stenting”,Circulation107:2908-2913; 2003.
Hamilton, A. et al., “Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substitutents on Affinity for the Adenine Nucleotide Sites”,J. Med. Chem., 19:1371-1377 (1976).
Hass, W., et al., “A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients,”N. Engl. J. Med., 321(8):501-507 (1989).
Hechler et al., “A Role of the Fast ATP-gated P2X1 Cation Channel in Thrombosis of Small Arteries in Vivo”,J. Exp. Med. 198:661-667:2003.
Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits,Arterioscl. Thromb. (1993) 13(8):1171-1179.
Hiratsuka, Toshiaki, “Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2′,3′-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives”Biochimica et Biophysica Acta(1982), 719(3), 509-17.
Hiratsuka T., “Affinity Labeling of the Myosin ATPase with Ribose-Modified Fluorescent Nucleotides and Vanadate”,J. Biochem., 96: 147-154 (1984).
Hiratsuka, Toshiaki, “Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP”Biophysical Journal(1997), 72(2, Pt. 1), 843-849.
Hourani et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, Mar. 29-31, 2000.
Hourani et al., “Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5′-dipho
Boyer José L.
Douglass, III James G.
Shaver Sammy R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick T
LandOfFree
Drug-eluting stents coated with P2Y 12 receptor antagonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug-eluting stents coated with P2Y 12 receptor antagonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug-eluting stents coated with P2Y 12 receptor antagonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023640